CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a biopharmaceutical company focused on oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders, announced today the presentation of results from its Phase II study of its product candidate ALTU-238 at The Third International Congress of the Growth Hormone Research Society and the Insulin-like Growth Factor Research Society, which is taking place this week in Kobe, Japan. ALTU-238 is being developed as a subcutaneously administered, once-per-week formulation of human growth hormone that employs Altus’ proprietary protein crystallization and formulation technology.
